Castle Biosciences has announced new positive results from an open-label study investigating IDgenetix, a guided medication management test for patients with neuropsychiatric conditions such as depression and anxiety.
The study compared outcomes between a previously published, multi-centre, randomised controlled trial (RCT) and real-world evidence (RWE) from a single-centre, non-randomised, open-label study for patients with major depressive disorder (MDD).
According to data from the RCT, IDgenetix-guided medication management showed a 37% improvement in response rates and a 49% improvement in remission rates compared to standard care. The RWE from a single-centre, open-label study demonstrated a 32% improvement in response rates and a 57% improvement in remission rates.
Castle Biosciences will share this data at the Neuroscience Education Institute (NEI) Congress taking place on 9-12 November 2023.
IDgenetix is an advanced pharmacogenomic (PGx) test designed to assist clinicians in selecting and managing medication for patients with neuropsychiatric conditions, such as depression and anxiety. The test identifies suitable medications by integrating drug-drug, drug-gene and lifestyle factor interactions into a clinically actionable report.
In the previously published RCT, the use of IDgenetix for medication management of patients with severe depression significantly improved patient outcomes after 12 weeks of treatment.
Castle Biosciences presented data from the real-world study at the American Psychiatric Association Annual Meeting held between 20-24 May in San Francisco, US.
Castle Biosciences R&D SVP Robert Cook said: “This study demonstrates the strong correlation between results from a real-world analysis of IDgenetix and a published RCT from Bradley and colleagues, which showed that patients whose medication management was guided by IDgenetix were 2.65 times more likely to achieve remission of depressive symptoms compared to patients whose medication management was not guided by the test.”
